

Special Issue

Tumor Immunopharmacology, 2nd Edition

Message from the Guest Editors

Modulation of the immune system has proven to be an effective way to reduce the progression of multiple tumors. Thus, the discovery of new immunotherapeutic agents is a rapidly growing field. At present, the arsenal of immunomodulators with potential clinical application includes multiple modalities of antibodies, small compounds, and peptides targeting immune signaling pathways, vaccines, and adoptive cell transfer. This Special Issue will provide a comprehensive overview of the development of new immunotherapeutic agents for cancer treatment in the pre-clinical, translational, and clinical settings. We invite authors to submit original research or review articles that analyze the mechanism of action, efficacy, safety, and/or pharmacokinetics of immunotherapeutics in relevant models of neoplastic diseases.

Guest Editors

Dr. Marco A. Velasco-Velázquez

School of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, Mexico

Dr. Nohemí Salinas-Jazmín

School of Medicine, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico

Deadline for manuscript submissions

27 April 2026



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/258140

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)